Home » Stocks » NTEC

Intec Pharma Ltd. (NTEC)

Stock Price: $3.88 USD -0.13 (-3.24%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $3.90 +0.02 (0.52%) Jun 11, 7:59 PM
Market Cap 18.71M
Revenue (ttm) n/a
Net Income (ttm) -14.49M
Shares Out 4.82M
EPS (ttm) -3.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $3.88
Previous Close $4.01
Change ($) -0.13
Change (%) -3.24%
Day's Open 4.04
Day's Range 3.80 - 4.08
Day's Volume 656,270
52-Week Range 2.20 - 15.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Looking for Reddit penny stocks to buy? Check these 3 out The post Hot Reddit Penny Stocks to Buy?

Other stocks mentioned: ABEV, CIDM
1 month ago - PennyStocks

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...

Other stocks mentioned: CRBP, GNLN, HUGE, IIPR, OGI
2 months ago - Schaeffers Research

NEW YORK, March 26, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...

2 months ago - PRNewsWire

NEW YORK, March 22, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intec Pharma Ltd.  ("Intec" or the "Co...

2 months ago - PRNewsWire

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...

Other stocks mentioned: GNLN, HEXO, IIPR, SNDL, VFF, YCBD
2 months ago - Schaeffers Research

JERUSALEM , March 16, 2021 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that it has filed its annual report on Form 10-K for the year ended December 31...

2 months ago - GlobeNewsWire

JERUSALEM, March 15, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") announced today that it has entered into a definitive agreement for a business combination with Deco...

2 months ago - PRNewsWire

Shares of Intec Pharma Ltd (NASDAQ:NTEC) surged today as it went from $3.46 per share yesterday to a day high of $7.12 -- which imputes a jump of 105.78%. This is why it happened.

6 months ago - Pulse2

Shares of NTEC stock are soaring on Wednesday after Intec Pharma announced a cannabinoid research collaboration with GW Pharma. The post Intec Pharma News: Why NTEC Stock Is on Fire Today appeared first...

6 months ago - InvestorPlace

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to watch in ...

Other stocks mentioned: CGC, APHA, CRON, GWPH, IIPR, VFF, XXII ...
7 months ago - Schaeffers Research

JERUSALEM, Nov. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended September 30, 2020 and provides a corpor...

7 months ago - PRNewsWire

JERUSALEM, Oct. 8, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of ...

8 months ago - PRNewsWire

JERUSALEM, Sept. 14, 2020 /PRNewswire/ -- Intec Pharma Ltd.

8 months ago - PRNewsWire

JERUSALEM, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into a definitive agreement with Aspire Capital Fund (“Asp...

10 months ago - GlobeNewsWire

JERUSALEM, Aug. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd.

10 months ago - PRNewsWire

Intec Pharma Ltd. (NTEC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Investors need to pay close attention to Intec Pharma (NTEC) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

JERUSALEM, May 28, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the Jefferies Virtual Healthcare Conferenc...

1 year ago - PRNewsWire

JERUSALEM , May 04, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into definitive agreements with several institutional and ...

1 year ago - GlobeNewsWire

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Other stocks mentioned: ARNA, CARA, CRBP, CRON, GNLN, GWPH, MBII ...
1 year ago - Investopedia

JERUSALEM, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of 16,250,...

1 year ago - GlobeNewsWire

Micro-cap Intec Pharma Ltd (NASDAQ: NTEC) shares are plummeting on heavy volume Monday following a clinical trial readout from the company.

1 year ago - Benzinga

Shares of biotech Intec Pharma Ltd. plunged 80% in premarket trade Monday after the company said its late-stage trial of a drug meant to treat symptoms of advanced Parkinson's disease did not result in ...

1 year ago - Market Watch

About NTEC

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which has completed a Phase III clinical trial for the treatment of Parkinson's disease symptoms in adv... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Jeffrey Meckler
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
NTEC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Intec Pharma stock is "Buy." The 12-month stock price forecast is 13.00, which is an increase of 235.05% from the latest price.

Price Target
$13.00
(235.05% upside)
Analyst Consensus: Buy